Trending News

The UK Medicines and Healthcare Products Regulatory Agency (MHRA) has approved a CBD/THC combination treatment under its Named Patient programme and other compassionate areas. Medlab’s NanaBis, to be used under NanaDol, a botanical version of NanaBis, has previously shown encouraging Phase I/II data for the treatment of cancer-induced bone pain and could be a potential […]

The first subject has been dosed in a Phase I biomarker study of apimostinel, a rapid-acting N-methyl-D-aspartate receptor (NMDAR) modulator for major depressive disorders (MDD).  The injectable treatment was developed by clinical-stage biotechnology company Gate Neurosciences for acute depressive disorders such as postpartum and episodic depression, and depression with suicidality.  Apimostinel previously demonstrated proof-of-concept in […]

Neuroscientists have identified and developed a new drug candidate that has the potential to effectively treat temporal lobe epilepsy (TLE) by suppressing neuroinflammation.  Although symptomatic medications are available, one-third of TLE patients remain unresponsive to current treatment, so new drug targets are critically needed. Most of these drugs target neurons and synapses in the brain, […]

England will become the first country in Europe to roll out darolutamide (Nubeqa) to patients whose prostate cancer has spread to other parts of the body.  The drug works by blocking androgen receptors in cancer cells, which in turn blocks the effect of testosterone that allows the cancer cells to survive and multiply. Studies show […]

It has been proven that prednisolone does not improve sense of smell after Covid-19 and that for most patients this gradually improves over time regardless of treatment.  The study authors from UMC Utrecht stated that they do not recommend prednisolone for patients with persistent smell and/or taste disorders after Covid-19.   The persistent loss of smell […]

For World Antimicrobial Awareness Week (18-24 November), DDW’s Diana Spencer provides an overview of the latest news in antimicrobial resistance and drug discovery.  1. New class of antibiotics for TB A first-in-class investigational antitubercular agent has shown early bactericidal activity with a low, once-daily oral dose after 14 days of treatment.   The Phase IIa study […]

An Oxford University study has provided the first evidence that antibiotic resistant bacteria can travel from the gut to the lung, increasing the risk of deadly infections.  The findings coincide with World Antimicrobial Awareness Week and shed light on how antimicrobial resistance (AMR) arises and persists.   The study, which has been published in Nature Communications […]

Developing new antibiotics is essential to winning the fight against resistant infections, the Association of the British Pharmaceutical Industry (ABPI) has said.  The comments come ahead of World Antimicrobial Awareness Week (18-24 November), which aims to improve the awareness and understanding of antimicrobial resistance (AMR).   The event seeks to encourage best practices among the public, health […]

A first-in-class investigational antitubercular agent has shown early bactericidal activity with a low, once-daily oral dose after 14 days of treatment.  The Phase IIa study evaluated GSK’s GSK3036656 in participants with drug-susceptible pulmonary tuberculosis. The company hopes GSK3036656 could be a component of simpler treatment regimens in the future which could help address the TB […]

For World Diabetes Day, DDW’s Diana Spencer provides an overview of the latest innovations in the treatment of the disease. Here are 2022’s five most significant discoveries (in no particular order):  1. Human beta cell model Earlier this year, Human Cell Design, a biotechnology company focused on generating translational human cellular models, launched Endoc-BH5 to […]